Kynamro

Chemical Namemipomersen sodium
Dosage FormInjection (subcutaneous; 200mg/mL)
Drug ClassInhibitors
SystemBlood
CompanyKastle Therapeutics
Approval Year2013

Indication

  • Used as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC), and non-high density lipoprotein-cholesterol (nonHDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Last updated on 4/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kynamro (mipomersen sodium) Prescribing Information2013Genzyme Corporation, Cambridge, MA